{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"50"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"}],"units":"Participants"}],"description":"The percentage of participants requiring low-dose bevcizumab or steroid due to an inflammatory reaction secondary to an immune response to lerapolturev treatment","groups":[{"description":"All participants received a single open-label infusion of lerapolturev","id":"OG000","title":"All Participants Treated"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"1 year","title":"Percentage of Participants Requiring Low-dose Bevacizumab or Steroid","type":"PRIMARY","unitOfMeasure":"percentage of participants"}